PMC5302182_01
Imaging showing treatment response to Erlotinib.
gr1.jpg
PMC5302182_01_gr1.jpg
fig1
The patient responded and remained well, in remission until February 2015 (Fig. 1).
Imaging showing treatment response to Osimertinib.
gr2.jpg
PMC5302182_01_gr2.jpg
fig2
February 2016 under the extended access programme. From this point forward, investigations show resolution of brain metastases and review is ongoing (Fig. 2).